Expertise in
18
conditions

Dr. Craig D. Lotterman

Pediatric Hematology Oncology
1315 Jefferson Highway, 
New Orleans, LA 
On Staff At
Accepting New Patients
Expertise in
18
conditions
1315 Jefferson Highway, 
New Orleans, LA 

Overview

Craig Lotterman is a Pediatric Hematologist Oncology provider practicing medicine in New Orleans, Louisiana.

Dr. Lotterman is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Rhabdoid Tumor, Hepatoblastoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

Dr. Lotterman is board certified in American Board Of Pediatrics - Pediatrics. He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 69 clinical trials. Dr. Lotterman is currently accepting new patients.

Graduate Institution

Chicago Medical Education, Medicine, 2003

Residency

NYU Pediatrics, Pediatrics, 2006

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in MD

Board Certifications

American Board Of Pediatrics - Pediatrics

Fellowships

Johns Hopkins University, Pediatric Hematology Oncology
Year Completed: 2009

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Magnolia Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Ochsner Children’s Health Center - New Orleans
1315 Jefferson Highway, New Orleans, LA 70121
Other Locations
Ochsner Children's Health Center - Pediatric Specialties Slidell
105 Medical Center Dr, Suite 305, Slidell, LA 70461
Terrebone General Medical Center
8120 Main St., Houma, LA 70360

Additional Areas of Focus

Dr. Lotterman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

69 Clinical Trials

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
View 9 Less Clinical Trials

10 Total Publications

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Journal: Journal of the National Cancer Institute
Published: May 20, 2025
Similar Doctors
Expertise in
4
conditions
Dr. Tammuella Singleton
Pediatric Hematology Oncology
Expertise in
4
conditions
Dr. Tammuella Singleton
Pediatric Hematology Oncology

Ochsner Children’s Health Center - New Orleans

1315 Jefferson Hwy, 
New Orleans, LA 
 (0.1 miles away)
504-842-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tammuella Singleton is a Pediatric Hematologist Oncology provider practicing medicine in New Orleans, Louisiana. Dr. Singleton is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Hemophilia B, Hemophilic Arthropathy, and Blood Clots. Dr. Singleton is board certified in American Board Of Pediatrics - Pediatric Hematology/Oncology. Dr. Singleton is currently accepting new patients.

Expertise in
37
conditions
Dr. Sun Y. Kim
Medical Genetics | Pediatrics | Pediatric Hematology Oncology
Expertise in
37
conditions
Dr. Sun Y. Kim
Medical Genetics | Pediatrics | Pediatric Hematology Oncology

Louisiana State University School Of Medicine In New Orleans Faculty G

2000 Canal St, 
New Orleans, LA 
 (3.7 miles away)
504-702-3000
Languages Spoken:
English
See accepted insurances

Sun Kim is a Medical Genetics specialist and a Pediatrics provider practicing medicine in New Orleans, Louisiana. Dr. Kim is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Chromosome 13q Deletion, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Cat Eye Syndrome.

Expertise in
0
conditions
Dr. Corey P. Falcon
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Corey P. Falcon
Pediatric Hematology Oncology

Ochsner Children’s Health Center - New Orleans

1315 Jefferson Highway, 
New Orleans, LA 
 (0.1 miles away)
504-842-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Falcon is a Pediatric Hematologist Oncology provider practicing medicine in New Orleans, Louisiana. His clinical expertise encompasses Anemia, Sickle Cell Disease, Infantile Neutropenia, and Immune Thrombocytopenic Purpura (ITP). Dr. Falcon is board certified in American Board Of Pediatrics - Pediatric Hematology/Oncology. Dr. Falcon is currently accepting new patients.

Frequently Asked Questions about Dr. Craig D. Lotterman

How do I make an appointment with Dr. Craig D. Lotterman?

You can book an appointment with Dr. Craig D. Lotterman by calling their office at 504-842-3900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig D. Lotterman a top-rated expert for Childhood Acute Myeloid Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig D. Lotterman is classified as an Advanced expert for Childhood Acute Myeloid Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig D. Lotterman specialize in?

While Dr. Craig D. Lotterman is a Pediatric Hematology Oncology, they have specific expertise in Childhood Acute Myeloid Leukemia, Rhabdoid Tumor, and Hepatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Craig D. Lotterman participate in research or clinical trials?

Yes. Dr. Craig D. Lotterman has published 10 articles and abstracts on conditions like Childhood Acute Myeloid Leukemia. You can view a list of Dr. Craig D. Lotterman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig D. Lotterman accept my insurance?

Dr. Craig D. Lotterman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 504-842-3900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lotterman's expertise for a condition
ConditionClose
      View All 18 Advanced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile